检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:曹玙 王倩[1] 刘振英[1] 孙国全[1] 郭丽洁[1]
机构地区:[1]中国医科大学附属第一医院检验科,辽宁沈阳110001
出 处:《中华医院感染学杂志》2016年第3期528-529,542,共3页Chinese Journal of Nosocomiology
基 金:国家自然科学基金资助项目(81271908)
摘 要:目的研究侵袭性肺炎链球菌感染的临床特征及耐药性,分析其流行趋势,为有效预防与控制侵袭性肺炎链球菌感染提供依据。方法回顾性调查医院2008年10月-2014年10月非重复分离的41株侵袭性肺炎链球菌感染患者临床资料及药敏试验数据,分析其流行特征及耐药性。结果侵袭性肺炎链球菌感染多发生于内科和儿科病区,以<60岁成人和<5岁儿童居多,感染季节多在冬春更替期或秋季,感染类型以血液感染为主;41例侵袭性肺炎链球菌感染患者科室分布以内科和儿科为主,分别占58.6%和39.0%;肺炎链球菌对红霉素、四环素和磺胺甲噁唑/甲氧苄啶的耐药率均>60.0%,对青霉素G耐药率达31.7%,未发现耐喹诺酮类、利奈唑胺和万古霉素菌株。结论加强侵袭性肺炎链球菌感染患者的目标性监测,明确其耐药特征,有利于预防与控制侵袭性肺炎链球菌感染及流行。OBJECTIVE To investigate the clinical feature and resistance of invasive Streptococcus pneumonia (Spn), analyze epidemic tendency and provide reference for prevention and control of invasive Spn infections. METHODS The clinical data and susceptibility testing data of 41 non-repetitive strains of invasive Spn in our hospi- tal from Oct. 2008 to Oct. 2014 were retrospectively reviewed to analyze epidemic tendency and resistance of inva- sire Spn. RESULTS Invasive Spn infections mainly distributed in medical wards (58. 6%) and pediatric wards (39.0%). The major patients with infections were adults 〈 60 years of age and children 〈 5 years of age. The infection usually occurred in the alteration of winter to spring and in autumn. The main type of infection was blood infection (85.4%). The invasive Spn strains had high resistance of 〉60.0% to erythromyein, tetracycline and trimethoprim/sulfamethoxazole. The resistance rate to penlcilllnis was up to 31.7%. There were no strains resist- ant to quinolones, linezolid and vaneomycin. CONCLUSION To strengthen objective monitor of patients with inva- sive Spn infection and clarify the resistance feature is beneficial for prevention and control of invasive Spn infection.
分 类 号:R378.12[医药卫生—病原生物学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:18.117.157.139